2016-03-10T00:00:00.000-05:00
Taylor Wealth Management,0.509318
hepatic infectious disease,-0.762958
Pharmaceuticals’s revenue,-0.510011
price target,-0.424268
Wealth Management Partners,0.509318
Oxford Asset Management,0.417495
DekaBank Deutsche Girozentrale,0.323472
Asset Management Inc.,0.400481
stock,0.027616
Reynolds Capital Management,0.273965
hold rating,-0.226161
InvestorPlace Broker Center,0.555736
biopharmaceutical company,0.40909
market outperform rating,0.322439
Fortaleza Asset Management,0.400481
personal trading style,0.598412
Leerink Swann,0.219157
buy rating,-0.226161
Market Beat.com reports,-0.325539
average price,0.404385
Alnylam Pharmaceuticals Inc.,0.560435
JPMorgan Chase,-0.101829
shares,-0.0269902
concise daily summary,0.448938
Alnylam Pharmaceuticals,-0.0913281
consensus target price,0.486761
stock broker,0.245696
mid-day trading,-0.424268
consensus rating,0.485731
hepatic infectious diseases,-0.777447
RNAi therapeutics,-0.56796
Asset Management,0.408988
quarterly earnings data,-0.310056
new stake,0.273965
quarter,-0.128948
